Novo Nordisk Company - Search News

The Motley Fool · 13h

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Seeking Alpha · 3d

Novo Nordisk: From Peak Performance To Needing A Booster Shot

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high profitability. Click here to read more.

Business Insider · 1d

Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price

Investing.com on MSN · 1d

BofA reiterates Buy on Novo Nordisk shares on performance

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting a significant downturn in the second half of 2024,

1d

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

1don MSN

Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...

1don MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

1d

LVMH overtakes Novo Nordisk as Europe’s most valuable company

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...

1don MSN

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk dropped precipitously Friday after a last-minute announcement from the Biden administration ...

1d

Novo's Ozempic, Wegovy picked for US Medicare price negotiations

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

2d

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

1d

Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

3d

Novo Nordisk: Excellent Opportunity To Buy The Dip

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results